Endocapillary proliferative glomerulonephritis
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Endocapillary proliferative glomerulonephritis Classification and external resources | |
| ICD-10 | N00.-N08. with .4 suffix |
|---|---|
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Endocapillary proliferative glomerulonephritis is a form of glomerulonephritis that can be associated with nephritis.[1]
It may be associated with Parvovirus B19.[2]
References
- ↑ Katano K, Hayatsu Y, Matsuda T, et al (November 2007). "Endocapillary proliferative glomerulonephritis with crescent formation and concurrent tubulointerstitial nephritis complicating retroperitoneal fibrosis with a high serum level of IgG4". Clin. Nephrol. 68 (5): 308–14. PMID 18044263.
- ↑ Iwafuchi Y, Morita T, Kamimura A, Kunisada K, Ito K, Miyazaki S (March 2002). "Acute endocapillary proliferative glomerulonephritis associated with human parvovirus B19 infection". Clin. Nephrol. 57 (3): 246–50. PMID 11924757.
Further reading
- Ito S, Kuriyama H, Iino N, et al (December 2003). "Patient with diffuse mesangial and endocapillary proliferative glomerulonephritis with hypocomplementemia and elevated anti-streptolysin O treated with prednisolone, angiotensin-converting enzyme inhibitor, and angiotensin II receptor antagonist". Clin. Exp. Nephrol. 7 (4): 290–5. doi:10.1007/s10157-003-0244-0. PMID 14712359.
- Kano K, Nishikura K, Kojima M, et al (June 2003). "A patient with membranoproliferative glomerulonephritis diagnosed by the third biopsy via endocapillary proliferative glomerulonephritis and focal membranoproliferative glomerulonephritis". Clin. Exp. Nephrol. 7 (2): 157–62. doi:10.1007/s10157-003-0231-5. PMID 14586735.
WikiDoc Research Resources for Endocapillary proliferative glomerulonephritis | |
|---|---|
| Articles on Endocapillary proliferative glomerulonephritis | Most recent articles on Endocapillary proliferative glomerulonephritis • Most cited articles on Endocapillary proliferative glomerulonephritis • Review articles on Endocapillary proliferative glomerulonephritis • Articles on Endocapillary proliferative glomerulonephritis in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Endocapillary proliferative glomerulonephritis | Powerpoint slides on Endocapillary proliferative glomerulonephritis • Images of Endocapillary proliferative glomerulonephritis • Photos of Endocapillary proliferative glomerulonephritis • Podcasts & MP3s on Endocapillary proliferative glomerulonephritis • Videos on Endocapillary proliferative glomerulonephritis |
| Evidence Based Medicine Regarding Endocapillary proliferative glomerulonephritis | Cochrane Collaboration on Endocapillary proliferative glomerulonephritis • Bandolier on Endocapillary proliferative glomerulonephritis • TRIP on Endocapillary proliferative glomerulonephritis |
| Cost Effectiveness of Endocapillary proliferative glomerulonephritis | Cost Effectiveness of Endocapillary proliferative glomerulonephritis |
| Clinical Trials Involving Endocapillary proliferative glomerulonephritis | Ongoing Trials on Endocapillary proliferative glomerulonephritis at Clinical Trials.gov • Trial results on Endocapillary proliferative glomerulonephritis • Clinical Trials on Endocapillary proliferative glomerulonephritis at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Endocapillary proliferative glomerulonephritis | US National Guidelines Clearinghouse on Endocapillary proliferative glomerulonephritis • NICE Guidance on Endocapillary proliferative glomerulonephritis • NHS PRODIGY Guidance • FDA on Endocapillary proliferative glomerulonephritis • CDC on Endocapillary proliferative glomerulonephritis |
| Textbook Information on Endocapillary proliferative glomerulonephritis | Books and Textbook Information on Endocapillary proliferative glomerulonephritis |
| Pharmacology Resources on Endocapillary proliferative glomerulonephritis | Dosing of Endocapillary proliferative glomerulonephritis • Drug interactions with Endocapillary proliferative glomerulonephritis • Side effects of Endocapillary proliferative glomerulonephritis • Allergic reactions to Endocapillary proliferative glomerulonephritis • Overdose information on Endocapillary proliferative glomerulonephritis • Carcinogenicity information on Endocapillary proliferative glomerulonephritis • Endocapillary proliferative glomerulonephritis in pregnancy • Pharmacokinetics of Endocapillary proliferative glomerulonephritis • |
| Genetics, Pharmacogenomics, and Proteinomics of Endocapillary proliferative glomerulonephritis | Genetics of Endocapillary proliferative glomerulonephritis • Pharmacogenomics of Endocapillary proliferative glomerulonephritis • Proteomics of Endocapillary proliferative glomerulonephritis |
| Newstories on Endocapillary proliferative glomerulonephritis | Endocapillary proliferative glomerulonephritis in the news • Be alerted to news on Endocapillary proliferative glomerulonephritis • News trends on Endocapillary proliferative glomerulonephritis |
| Commentary on Endocapillary proliferative glomerulonephritis | Blogs on Endocapillary proliferative glomerulonephritis |
| Patient Resources on Endocapillary proliferative glomerulonephritis | Patient resources on Endocapillary proliferative glomerulonephritis • Discussion groups on Endocapillary proliferative glomerulonephritis • Patient Handouts on Endocapillary proliferative glomerulonephritis • Directions to Hospitals Treating Endocapillary proliferative glomerulonephritis • Risk calculators and risk factors for Endocapillary proliferative glomerulonephritis |
| Healthcare Provider Resources on Endocapillary proliferative glomerulonephritis | Symptoms of Endocapillary proliferative glomerulonephritis • Causes & Risk Factors for Endocapillary proliferative glomerulonephritis • Diagnostic studies for Endocapillary proliferative glomerulonephritis • Treatment of Endocapillary proliferative glomerulonephritis |
| Continuing Medical Education (CME) Programs on Endocapillary proliferative glomerulonephritis | CME Programs on Endocapillary proliferative glomerulonephritis |
| International Resources on Endocapillary proliferative glomerulonephritis | Endocapillary proliferative glomerulonephritis en Espanol • Endocapillary proliferative glomerulonephritis en Francais |
| Business Resources on Endocapillary proliferative glomerulonephritis | Endocapillary proliferative glomerulonephritis in the Marketplace • Patents on Endocapillary proliferative glomerulonephritis |
| Informatics Resources on Endocapillary proliferative glomerulonephritis | List of terms related to Endocapillary proliferative glomerulonephritis |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
